Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism
Feifei Han,1,* Haiping Wang,1,2,* Li Wang,1 Limei Fan,1 Sibei Peng,1 Xiaoying Hou,1,2 Xiji Shu,1,2 Binlian Sun,1,2 Yuchen Liu1,2 1Cancer Institute, School of Medicine, Jianghan University, Wuhan, Hubei, 430056, People’s Republic of China; 2Hubei Key Laboratory of Cognitive an...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-05-01
|
| Series: | International Journal of Nanomedicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/carrier-free-silibininsorafenib-microparticles-alleviate-metabolic-dys-peer-reviewed-fulltext-article-IJN |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849417994705305600 |
|---|---|
| author | Han F Wang H Wang L Fan L Peng S Hou X Shu X Sun B Liu Y |
| author_facet | Han F Wang H Wang L Fan L Peng S Hou X Shu X Sun B Liu Y |
| author_sort | Han F |
| collection | DOAJ |
| description | Feifei Han,1,* Haiping Wang,1,2,* Li Wang,1 Limei Fan,1 Sibei Peng,1 Xiaoying Hou,1,2 Xiji Shu,1,2 Binlian Sun,1,2 Yuchen Liu1,2 1Cancer Institute, School of Medicine, Jianghan University, Wuhan, Hubei, 430056, People’s Republic of China; 2Hubei Key Laboratory of Cognitive and Affective Disorders, Jianghan University, Wuhan, Hubei, 430056, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yuchen Liu, Email yuchen.liu@jhun.edu.cnIntroduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by excessive fat accumulation in the liver, is the most prevalent cause of chronic liver disease globally. The clinical use of pharmacological agents such as silibinin and sorafenib is limited due to poor water solubility, low bioavailability, and potential side effects, necessitating innovative therapeutic approaches.Methods: In this study, we developed self-assembled, carrier-free microparticles of silibinin and sorafenib (SIL-SOR-MPs) using magnetic stirring and evaluated their therapeutic effects on MASLD both in vitro and in vivo.Results: Compared to free SIL and free SOR, SIL-SOR-MPs significantly reduced lipid accumulation in HepG2 cells and effectively alleviated hepatic steatosis and liver damage in mice. Mechanistic investigations further showed that SIL-SOR-MPs more effectively down-regulated lipid synthesis genes and up-regulated genes involved in lipid oxidation.Discussion: In summary, our study highlights that carrier-free SIL-SOR-MPs demonstrate the ability to reverse the progression of MASLD and present a promising therapeutic strategy.Keywords: metabolic dysfunction-associated steatotic liver disease, silibinin, sorafenib, self-assembled carrier-free microparticles, fatty acid metabolism |
| format | Article |
| id | doaj-art-7ddf97774fba420daec9eff9bdbfdbe2 |
| institution | Kabale University |
| issn | 1178-2013 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of Nanomedicine |
| spelling | doaj-art-7ddf97774fba420daec9eff9bdbfdbe22025-08-20T03:32:33ZengDove Medical PressInternational Journal of Nanomedicine1178-20132025-05-01Volume 20Issue 169496962103415Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid MetabolismHan F0Wang H1Wang LFan L2Peng SHou X3Shu X4Sun B5Liu Y6Jianghan universitySchool of MedicineCancer Institute, School of MedicineSchool of MedicinePathology and Pathophysiology, School of MedicineSchool of MedicineSchool of MedicineFeifei Han,1,* Haiping Wang,1,2,* Li Wang,1 Limei Fan,1 Sibei Peng,1 Xiaoying Hou,1,2 Xiji Shu,1,2 Binlian Sun,1,2 Yuchen Liu1,2 1Cancer Institute, School of Medicine, Jianghan University, Wuhan, Hubei, 430056, People’s Republic of China; 2Hubei Key Laboratory of Cognitive and Affective Disorders, Jianghan University, Wuhan, Hubei, 430056, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yuchen Liu, Email yuchen.liu@jhun.edu.cnIntroduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by excessive fat accumulation in the liver, is the most prevalent cause of chronic liver disease globally. The clinical use of pharmacological agents such as silibinin and sorafenib is limited due to poor water solubility, low bioavailability, and potential side effects, necessitating innovative therapeutic approaches.Methods: In this study, we developed self-assembled, carrier-free microparticles of silibinin and sorafenib (SIL-SOR-MPs) using magnetic stirring and evaluated their therapeutic effects on MASLD both in vitro and in vivo.Results: Compared to free SIL and free SOR, SIL-SOR-MPs significantly reduced lipid accumulation in HepG2 cells and effectively alleviated hepatic steatosis and liver damage in mice. Mechanistic investigations further showed that SIL-SOR-MPs more effectively down-regulated lipid synthesis genes and up-regulated genes involved in lipid oxidation.Discussion: In summary, our study highlights that carrier-free SIL-SOR-MPs demonstrate the ability to reverse the progression of MASLD and present a promising therapeutic strategy.Keywords: metabolic dysfunction-associated steatotic liver disease, silibinin, sorafenib, self-assembled carrier-free microparticles, fatty acid metabolismhttps://www.dovepress.com/carrier-free-silibininsorafenib-microparticles-alleviate-metabolic-dys-peer-reviewed-fulltext-article-IJNMetabolic dysfunction-associated steatotic liver diseaseSilibininSorafenibSelf-assembled carrier-free microparticlesFatty acid metabolism |
| spellingShingle | Han F Wang H Wang L Fan L Peng S Hou X Shu X Sun B Liu Y Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism International Journal of Nanomedicine Metabolic dysfunction-associated steatotic liver disease Silibinin Sorafenib Self-assembled carrier-free microparticles Fatty acid metabolism |
| title | Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism |
| title_full | Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism |
| title_fullStr | Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism |
| title_full_unstemmed | Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism |
| title_short | Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism |
| title_sort | carrier free silibinin sorafenib microparticles alleviate metabolic dysfunction associated steatotic liver disease by modulating fatty acid metabolism |
| topic | Metabolic dysfunction-associated steatotic liver disease Silibinin Sorafenib Self-assembled carrier-free microparticles Fatty acid metabolism |
| url | https://www.dovepress.com/carrier-free-silibininsorafenib-microparticles-alleviate-metabolic-dys-peer-reviewed-fulltext-article-IJN |
| work_keys_str_mv | AT hanf carrierfreesilibininsorafenibmicroparticlesalleviatemetabolicdysfunctionassociatedsteatoticliverdiseasebymodulatingfattyacidmetabolism AT wangh carrierfreesilibininsorafenibmicroparticlesalleviatemetabolicdysfunctionassociatedsteatoticliverdiseasebymodulatingfattyacidmetabolism AT wangl carrierfreesilibininsorafenibmicroparticlesalleviatemetabolicdysfunctionassociatedsteatoticliverdiseasebymodulatingfattyacidmetabolism AT fanl carrierfreesilibininsorafenibmicroparticlesalleviatemetabolicdysfunctionassociatedsteatoticliverdiseasebymodulatingfattyacidmetabolism AT pengs carrierfreesilibininsorafenibmicroparticlesalleviatemetabolicdysfunctionassociatedsteatoticliverdiseasebymodulatingfattyacidmetabolism AT houx carrierfreesilibininsorafenibmicroparticlesalleviatemetabolicdysfunctionassociatedsteatoticliverdiseasebymodulatingfattyacidmetabolism AT shux carrierfreesilibininsorafenibmicroparticlesalleviatemetabolicdysfunctionassociatedsteatoticliverdiseasebymodulatingfattyacidmetabolism AT sunb carrierfreesilibininsorafenibmicroparticlesalleviatemetabolicdysfunctionassociatedsteatoticliverdiseasebymodulatingfattyacidmetabolism AT liuy carrierfreesilibininsorafenibmicroparticlesalleviatemetabolicdysfunctionassociatedsteatoticliverdiseasebymodulatingfattyacidmetabolism |